With second deal, MFN comes into focus

With a second “most favored nation” pricing deal, elements of the Trump administration’s drug pricing strategy came into focus last week, but many of the critical parameters remain murky. The biggest unanswered question is whether the MFN agreements are the end or the beginning of the administration’s attempts to restructure the U.S. pharmaceutical market.

Oval office press conferences Friday with AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and the prior week with Pfizer Inc. (NYSE:PFE) showcased how the Trump administration is blending populist politics, economic nationalism, and industrial policy to reshape the life sciences sector. ...